CHIKV Envelope Antigen 2 (aa 339-692) [His] (DAGA-259)

CHIKV Envelope Antigen 2 (aa 339-692) [His], recombinant protein from E.coli

Alternative Names
Chikungunya virus envelope protein; CHIKV E2 protein; CHIKV E2; CHIKV Envelope Antigen 2; CHIKV
>95% , based on SDS PAGE
Batch dependent - please inquire should you have specific requirements.
100 μg, 1 mg
In PBS with 8M Urea
Keep it at 4˚C if used within a month. For long term storage, split it into small aliquots and keep at -80˚C. Avoid repeated freezing and thawing. The product will be expired one year after receiving if stored properly. Non-hazardous. No MSDS required.
Antigen Description
A member of the Togaviridae family, and Alphavirus genus, belonging to the Semliki Forest serological complex. CHIKV is a spherical enveloped virion that measures 60 to 70 nm in diameter, and contains a single-stranded, positive-sense RNA genome.
Chikungunya virus envelope protein;CHIKV E2 protein;CHIKV E2;CHIKV Envelope Antigen 2;CHIKV


Have you cited DAGA-259 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Macrophage scavenger receptor 1 controls Chikungunya virus infection through autophagy in mice


Authors: Yang, Long; Geng, Tingting; Yang, Guang; Ma, Jinzhu; Wang, Leilei; Ketkar, Harshada; Yang, Duomeng; Lin, Tao; Hwang, Jesse; Zhu, Shu; Wang, Yanlin; Dai, Jianfeng; You, Fuping; Cheng, Gong; Vella, Anthony T.; Flavell, Richard. A.; Fikrig, Erol; Wang, Penghua

UsingMsr1knockout mice, Long Yang et al. demonstrate that macrophage scavenger receptor 1 (MSR1) activates autophagy to restrict the proliferation of Chikungunya virus, an alphavirus that causes crippling joint stiffness. This study provides insights into how host cellular machinery fights off Chikungunya virus. Macrophage scavenger receptor 1 (MSR1) mediates the endocytosis of modified low-density lipoproteins and plays an important antiviral role. However, the molecular mechanism underlying MSR1 antiviral actions remains elusive. We report that MSR1 activates autophagy to restrict infection of Chikungunya virus (CHIKV), an arthritogenic alphavirus that causes acute and chronic crippling arthralgia. Msr1 expression was rapidly upregulated after CHIKV infection in mice.Msr1knockout mice had elevated viral loads and increased susceptibility to CHIKV arthritis along with a normal type I IFN response. Induction of LC3 lipidation by CHIKV, a marker of autophagy, was reduced inMsr1(-/-)cells. Mechanistically, MSR1 interacted with ATG12 through its cytoplasmic tail and this interaction was enhanced by CHIKV nsP1 protein. MSR1 repressed CHIKV replication through ATG5-ATG12-ATG16L1 and this was dependent on the FIP200-and-WIPI2-binding domain, but not the WD40 domain of ATG16L1. Our results elucidate an antiviral role for MSR1 involving the autophagic function of ATG5-ATG12-ATG16L1.

The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates


Authors: Prow, Natalie A.; Liu, Liang; McCarthy, Mary K.; Walters, Kevin; Kalkeri, Raj; Geiger, Jillian; Koide, Fusataka; Cooper, Tamara H.; Eldi, Preethi; Nakayama, Eri; Diener, Kerrilyn R.; Howley, Paul M.; Hayball, John D.; Morrison, Thomas E.; Suhrbier, Andreas

The Sementis Copenhagen Vector (SCV) is a new vaccinia virus-derived, multiplication-defective, vaccine technology assessed herein in non-human primates. Indian rhesus macaques (Macaca mulatta) were vaccinated with a multi-pathogen recombinant SCV vaccine encoding the structural polyproteins of both Zika virus (ZIKV) and chikungunya virus (CHIKV). After one vaccination, neutralising antibody responses to ZIKV and four strains of CHIKV, representative of distinct viral genotypes, were generated. A second vaccination resulted in significant boosting of neutralising antibody responses to ZIKV and CHIKV. Following challenge with ZIKV, SCV-ZIKA/CHIK-vaccinated animals showed significant reductions in viremias compared with animals that had received a control SCV vaccine. Two SCV vaccinations also generated neutralising and IgG ELISA antibody responses to vaccinia virus. These results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket